

Supporting Information

Access to Functionalized Thienopyridines via a Reagent-Capsule-Assisted Coupling, Thiolation and Cyclization Cascade Sequence

Jialing Cai, Shuo Huang, Ruenfa He, Lu Chen, Donghan Chen, Shaohua Jiang, Bin Li* and Yibiao Li*

Address: School of Chemical & Environmental Engineering, Wuyi University, Jiangmen, Guangdong Province, 529090, China

Email: Bin Li - andonlee@163.com; Yibiao Li - leeyib268@126.com

I. General methods and materials

Unless otherwise noted, all commercial materials and solvents were used without further purification. ^1H NMR spectra were recorded in CDCl_3 at 400 MHz and ^{13}C NMR spectra were recorded in CDCl_3 at 100 MHz respectively, ^1H and ^{13}C NMR were referenced to CDCl_3 at δ 7.260 and 77.0 respectively. The different types of carbon in the structures have been identified by HSQC, HMBC and DEPT techniques. GC-MS was obtained using electron ionization. HRMS was carried out on a MAT 95XP (Thermo). IR spectra were obtained as potassium bromide pellets or as liquid films between two potassium bromide pellets with a Bruker Vector 22 spectrometer. TLC was performed using commercially prepared 100-400 mesh silica gel plates (GF_{254}), and visualization was effected at 254 nm. All the other chemicals were purchased from Aldrich Chemicals. Commercial reagents were used without further purification.

II. General methods for the preparation of paraffin wax capsules containing potassium ethylxanthate

Paraffin wax (mp. 62-65 °C) was placed in a beaker (200 mL) and heated to 70-75 °C. Then molten, the volume of the molten wax was approximately 150 mL. A room temperature glass rod was repeatedly dipped into the molten wax (to a depth of 4-5 cm) 5-7 times to develop a wax coating on the glass rod. The coated rod of wax was allowed to cool to room temperature and the wax coating was removed from the glass rod to provide a hollow paraffin wax cone shell. The shell is charged with EtOC(S)SK (160 mg, 1.0 mmol) respectively. And then 3-4 drops of molten wax were dropped onto the EtOC(S)SK crystal to seal the open end of capsules. Once sealed, the extra wax was trimmed with a razor blade and dipped quickly into the molten wax to secure the seal. ^[1]




Figure S1. The glass rod for preparing paraffin wax capsules.





Figure S2. The finished hollow wax shell.



Figure S3. The finished paraffin wax capsule.

III. Optimization of reaction conditions

Table S1. Optimization of reaction conditions^{a, b}



Entry	Variations from the standard conditions	Yield ^(%)	
		3a	4a
1	-	88	0
2	EtOCS ₂ K without in paraffin wax capsule	0	0
3	(NH ₄) ₂ S (2.0 equiv) instead of EtOCS ₂ K in capsule	0	0
4	Na ₂ S·9H ₂ O (2.0 equiv) instead of EtOCS ₂ K in capsule	23	69
5	thiourea (2.0 equiv) instead of EtOCS ₂ K in capsule	0	0
6	DMF instead of DMSO	75	0
7	toluene instead of DMSO	< 5	0
8	CH ₃ CN instead of DMSO	< 5	0
9	NaOH (2.0 equiv) instead of EtOCS ₂ K in capsule	0	87
10	Cs ₂ CO ₃ (2.0 equiv) instead of Et ₃ N	25	0
11	Diisopropylamine (4.0 equiv) instead of Et ₃ N	85	0
12	DBU (4.0 equiv) instead of Et ₃ N	65	0
13	3-bromo-2-fluoropyridine instead of 1a	73	0
14	2-bromo-3-iodopyridine instead of 1a	31	0
15	Pd(PPh ₃) ₄ (10 mmol%) instead of PdCl ₂ (PPh ₃) ₂	56	0
16	Pd(OAc) ₂ (5 mmol%) instead of PdCl ₂ (PPh ₃) ₂	43	0

^a Reaction conditions: fluoroiodopyridine **1** (1.0 mmol), terminal alkyne **2** (1.3 mmol), PdCl₂(PPh₃)₂ (5 mol%), CuI (10 mol%), Et₃N (4.0 mmol), DMSO (2 mL) and paraffin wax capsule (NaOH (2.0 mmol) at 35 °C for 10 h, then 90 °C for 12 h. ^b Yields are given for isolated products. EtOCS₂K=Potassium Ethylxanthate.

IV. General methods for the synthesis of furopyridines


A 25 mL Schlenk tube was charged with PdCl₂(PPh₃)₂ (35 mg, 5 mol%), CuI (19 mg, 10 mol%), one paraffin wax capsule of NaOH (80 mg) and a magnetic stirring bar. Then under

nitrogen, DMSO (2 mL) solution of 2-fluoro-3-iodopyridine (1.0 mmol), terminal alkyne (1.3 mmol), Et₃N (400 mg, 4.0 mmol) were injected by syringe. The reaction was performed for 10 h at 35 °C. Then the temperature was elevated to 80 °C for 12 h. After the reaction finished, the reaction mixture was diluted with ethyl acetate and passed through Celite. After evaporation of the solvent the residue was adsorbed on silica gel and the crude product was purified by column chromatography using n-hexane/ethyl acetate (10:1) as eluent.

V General methods for the synthesis of thienopyridine and related heterocycles


A 25 mL Schlenk tube was charged with PdCl₂(PPh₃)₂ (35 mg, 5 mol%), CuI (19 mg, 10 mol%), two paraffin wax capsule of EtOCS₂K (160 mg/capsule) and a magnetic stirring bar. Then under nitrogen, DMSO (2 mL) solution of 2-fluoro-3-iodopyridine (1.0 mmol), terminal alkyne (1.3 mmol), Et₃N (400 mg, 4.0 mmol) were injected by syringe. The reaction was performed for 10 h at 35 °C. Then the temperature was elevated to 90 °C for 12 h. After the reaction finished, the reaction mixture was diluted with ethyl acetate and passed through Celite. After evaporation of the solvent the residue was adsorbed on silica gel and the crude product was purified by column chromatography using n-hexane/ethyl acetate (10:1) as eluent.

VI. Characterization data for all prepared compounds



2-phenylthieno[2,3-*b*]pyridine ^[2]


¹H NMR (CDCl₃, 400 MHz) δ 8.46 (d, *J* = 4.4 Hz, 1H), 7.92 – 7.84 (m, 1H), 7.64 (d, *J* = 7.2 Hz, 2H), 7.42 – 7.27 (m, 4H), 7.22 – 7.14 (m, 1H); ¹³C NMR (CDCl₃, 100 MHz) δ 161.3, 146.1, 144.2, 134.0, 133.6, 130.4, 128.8 (2C), 128.6, 126.3 (2C), 119.6, 116.5; MS (EI, 70 eV) *m/z* (%): 211, 166, 139.



2-*m*-tolylthieno[2,3-*b*]pyridine


¹H NMR (CDCl₃, 400 MHz) δ 8.54 (d, *J* = 3.6 Hz, 1H), 8.02 (dd, *J* = 8.0, 1.6 Hz, 1H), 7.61 – 7.51 (m, 2H), 7.47 (s, 1H), 7.39 – 7.33 (m, 1H), 7.33 – 7.28 (m, 1H), 7.22 (d, *J* = 7.6 Hz, 1H), 2.45 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz) δ 161.5, 146.2, 144.7, 138.8, 134.2, 133.7, 130.6,

129.6, 128.9, 127.3, 123.7, 119.7, 116.5; MS (EI, 70 eV) m/z (%): 225, 191, 177, 111, 73; HRMS (EI) calcd for $C_{14}H_{11}NS$ (M^+) 225.0612; found, 225.0606.




2-(4-ethylphenyl)thieno[2,3-*b*]pyridine

1H NMR ($CDCl_3$, 400 MHz) δ 8.62 – 8.48 (m, 1H), 8.00 (dd, $J = 8.0, 1.2$ Hz, 1H), 7.67 (d, $J = 8.1$ Hz, 2H), 7.43 (s, 1H), 7.29 (t, $J = 7.0$ Hz, 3H), 2.72 (q, $J = 7.6$ Hz, 2H), 1.30 (t, $J = 7.6$ Hz, 3H); ^{13}C NMR ($CDCl_3$, 100 MHz) δ 161.4, 146.1, 145.3, 144.7, 134.3, 131.3, 130.4, 128.5 (2C), 126.5 (2C), 119.7, 116.0, 28.6, 15.4; MS (EI, 70 eV) m/z (%): 239, 225, 166; HRMS (EI) calcd for $C_{15}H_{13}NS$ (M^+) 239.0769; found, 239.0761.




2-(2,4-dimethylphenyl)thieno[2,3-*b*]pyridine

1H NMR ($CDCl_3$, 400 MHz) δ 8.57 (d, $J = 4.4$ Hz, 1H), 8.04 (dd, $J = 8.0, 1.6$ Hz, 1H), 7.40 (d, $J = 7.6$ Hz, 1H), 7.32 (dd, $J = 8.0, 4.6$ Hz, 1H), 7.17 (s, 1H), 7.16 (s, 1H), 7.11 (d, $J = 7.8$ Hz, 1H), 2.48 (s, 3H), 2.40 (s, 3H); ^{13}C NMR ($CDCl_3$, 100 MHz) δ 161.9, 145.97, 144.1, 138.6, 136.1, 133.6, 131.6, 130.8, 130.5 (2C), 126.7, 120.0, 119.5, 21.1, 20.9; MS (EI, 70 eV) m/z (%): 239, 224, 116; HRMS (EI) calcd for $C_{15}H_{13}NS$ (M^+) 239.0769; found, 239.0760.




2-(4-butylphenyl)thieno[2,3-*b*]pyridine

1H NMR ($CDCl_3$, 400 MHz) δ 8.52 (d, $J = 4.4$ Hz, 1H), 7.99 (dd, $J = 8.0, 1.2$ Hz, 1H), 7.65 (d, $J = 8.0$ Hz, 2H), 7.42 (s, 1H), 7.28 (t, $J = 6.4$ Hz, 3H), 2.67 (t, $J = 7.6$ Hz, 2H), 1.71 – 1.59 (m, 2H), 1.47 – 1.35 (m, 2H), 0.97 (t, $J = 7.2$ Hz, 3H); ^{13}C NMR ($CDCl_3$, 100 MHz) δ 161.4, 146.0, 144.7, 143.9, 134.3, 131.2, 130.4, 129.0 (2C), 126.4 (2C), 119.7, 115.9, 35.3, 33.4, 22.3, 13.9; MS (EI, 70 eV) m/z (%): 267, 224, 207; HRMS (EI) calcd for $C_{17}H_{17}NS$ (M^+) 267.1082; found, 267.1077.




2-(4-methoxyphenyl)thieno[2,3-*b*]pyridine^[2]

¹H NMR (CDCl₃, 400 MHz) δ 8.50 (dd, $J = 4.6, 1.5$ Hz, 1H), 7.98 (dd, $J = 8.0, 1.5$ Hz, 1H), 7.75 – 7.59 (m, 2H), 7.34 (s, 1H), 7.31 – 7.23 (m, 1H), 7.06 – 6.92 (m, 2H), 3.88 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz) δ 161.3, 160.2, 145.9, 144.4, 134.4, 130.2, 127.8 (2C), 126.5, 119.7, 115.3, 114.4 (2C), 7 55.4; MS (EI, 70 eV) m/z (%): 241, 226, 198.




N,N-dimethyl-4-(thieno[2,3-*b*]pyridin-2-yl)benzenamine

¹H NMR (CDCl₃, 400 MHz) δ 8.43 (d, $J = 4.0$ Hz, 1H), 7.91 (d, $J = 8.0$ Hz, 1H), 7.60 (d, $J = 8.8$ Hz, 2H), 7.26 – 7.17 (m, 2H), 6.75 (d, $J = 8.8$ Hz, 2H), 3.01 (s, 6H); ¹³C NMR (CDCl₃, 100 MHz) δ 161.0, 150.7, 145.2, 134.8, 129.7, 127.5 (4C), 121.9, 119.6, 113.6, 112.3, 40.34 (2C); MS (EI, 70 eV) m/z (%): 254, 238, 210, 126; HRMS (EI) calcd for C₁₅H₁₄N₂S (M⁺) 254.0878; found, 254.0872.



2-(2-fluorophenyl)thieno[2,3-*b*]pyridine


¹H NMR (CDCl₃, 400 MHz) δ 8.53 (d, $J = 4.5$ Hz, 1H), 8.00 (d, $J = 8.0$ Hz, 1H), 7.67 (t, $J = 7.6$ Hz, 1H), 7.61 (s, 1H), 7.36 – 7.24 (m, 2H), 7.24 – 7.11 (m, 2H); ¹³C NMR (CDCl₃, 100 MHz) δ 161.2 (d, $J_{C-F} = 2.9$ Hz, 1C), 159.6 (d, $J_{C-F} = 250.3$ Hz, 1C), 146.6, 137.6 (d, $J_{C-F} = 3.5$ Hz, 1C), 133.7, 130.9, 129.9 (d, $J_{C-F} = 8.6$ Hz, 1C), 129.5 (d, $J_{C-F} = 2.9$ Hz, 1C), 124.6 (d, $J_{C-F} = 3.6$ Hz, 1C), 121.6 (d, $J_{C-F} = 11.8$ Hz, 1C), 120.7 (d, $J_{C-F} = 9.3$ Hz, 1C), 119.7, 116.5, 116.3; MS (EI, 70 eV) m/z (%): 229, 210, 184, 114; HRMS (EI) calcd for C₁₃H₈FNS (M⁺) 229.0361; found, 229.0354.



2-(3-fluorophenyl)thieno[2,3-*b*]pyridine^[2]


¹H NMR (CDCl₃, 400 MHz) δ 8.54 (d, $J = 4.2$ Hz, 1H), 8.02 (d, $J = 8.0$ Hz, 1H), 7.54 – 7.38 (m, 4H), 7.30 (dd, $J = 7.2, 5.3$ Hz, 1H), 7.08 (t, $J = 8.4$ Hz, 1H); ¹³C NMR (CDCl₃, 100 MHz)

δ 163.0 (d, J_{C-F} = 245.2 Hz, 1C), 161.4, 146.6, 142.9, 135.9 (d, J_{C-F} = 8.1 Hz, 1C), 133.9, 130.9, 130.6 (d, J_{C-F} = 8.4 Hz, 1C), 122.2 (d, J_{C-F} = 2.8 Hz, 1C), 119.9, 117.5, 115.6 (d, J_{C-F} = 22.1 Hz, 1C), 113.2 (d, J_{C-F} = 22.8 Hz, 1C); MS (EI, 70 eV) m/z (%): 229, 184, 157, 114.




2-(4-chlorophenyl)thieno[2,3-*b*]pyridine

^1H NMR (CDCl_3 , 400 MHz) δ 8.55 (d, J = 4.4 Hz, 1H), 8.03 (d, J = 8.0 Hz, 1H), 7.66 (d, J = 8.2 Hz, 2H), 7.43 (d, J = 9.4 Hz, 3H), 7.36 – 7.28 (m, 1H); ^{13}C NMR (CDCl_3 , 100 MHz) δ 161.5, 146.6, 143.1, 134.7, 134.1, 132.3, 130.8, 129.2 (2C), 127.7 (2C), 119.9, 117.1; MS (EI, 70 eV) m/z (%): 245, 210, 166; HRMS (EI) calcd for $\text{C}_{13}\text{H}_8\text{ClNS}$ (M^+) 245.0066; found, 245.0061.




2-(2-chlorophenyl)thieno[2,3-*b*]pyridine

^1H NMR (CDCl_3 , 400 MHz) δ 8.56 (s, 1H), 8.02 (dd, J = 8.0, 1.2 Hz, 1H), 7.61 – 7.53 (m, 1H), 7.52 – 7.45 (m, 2H), 7.26-7.33 (m, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ 161.9, 146.5, 140.6, 132.7, 132.7, 133.2, 131.8, 131.0, 130.6, 129.6, 127.0, 121.8, 119.7; MS (EI, 70 eV) m/z (%): 245, 210, 166; HRMS (EI) calcd for $\text{C}_{13}\text{H}_8\text{ClNS}$ (M^+) 245.0066; found, 245.0064.




2-(3-bromophenyl)thieno[2,3-*b*]pyridine

^1H NMR (CDCl_3 , 400 MHz) δ 8.44 (d, J = 4.6 Hz, 1H), 7.92 (d, J = 8.0 Hz, 1H), 7.76 (s, 1H), 7.53 (d, J = 7.6 Hz, 1H), 7.40 (d, J = 8.0 Hz, 1H), 7.35 (s, 1H), 7.26 – 7.15 (m, 2H); ^{13}C NMR (CDCl_3 , 100 MHz) δ 161.5, 146.7, 142.6, 135.8, 133.9, 131.6, 130.9, 130.5, 129.3, 125.2, 123.1, 119.9, 117.6; MS (EI, 70 eV) m/z (%): 291, 289, 211, 209, 166, 139; HRMS (EI) calcd for $\text{C}_{13}\text{H}_8\text{BrNS}$ (M^+) 288.9561; found, 288.9556.




2-(4-bromophenyl)thieno[2,3-*b*]pyridine^[2]

¹H NMR (CDCl₃, 400 MHz) δ 8.55 (d, J = 4.6 Hz, 1H), 8.03 (d, J = 8.0 Hz, 1H), 7.59 (s, 4H), 7.46 (s, 1H), 7.37 – 7.28 (m, 1H); ¹³C NMR (CDCl₃, 100 MHz) δ 161.4, 146.6, 143.1, 134.1, 132.8, 132.2 (2C), 130.8, 128.0 (2C), 122.9, 119.9, 117.1; MS (EI, 70 eV) m/z (%): 291, 289, 245, 166.




2-(4-(trifluoromethyl)phenyl)thieno[2,3-*b*]pyridine

¹H NMR (CDCl₃, 400 MHz) δ 8.56 (d, J = 4.0 Hz, 1H), 8.05 (d, J = 8.0 Hz, 1H), 7.82 (d, J = 8.0 Hz, 2H), 7.69 (d, J = 8.0 Hz, 2H), 7.54 (s, 1H), 7.32 (dd, J = 7.6, 4.7 Hz, 1H); ¹³C NMR (CDCl₃, 100 MHz) δ 161.7, 147.0, 142.6, 137.3, 134.0, 131.1, 126.7 (4C), 126.0 (q, J = 3.7 Hz, 1C), 120.1, 118.3; MS (EI, 70 eV) m/z (%): 279, 278, 260, 257, 239; HRMS (EI) calcd for C₁₄H₈F₃NS (M⁺) 279.0330; found, 279.0324.




2-(thiophen-3-yl)thieno[2,3-*b*]pyridine^[2]

¹H NMR (CDCl₃, 400 MHz) δ 8.50 (d, J = 4.4 Hz, 1H), 7.97 (d, J = 8.0 Hz, 1H), 7.56 (d, J = 0.9 Hz, 1H), 7.42 (s, 2H), 7.32 (s, 1H), 7.26 (t, J = 4.0 Hz, 1H); ¹³C NMR (CDCl₃, 100 MHz) δ 161.0, 146.1, 139.2, 135.3, 134.1, 130.5, 126.9, 125.8, 122.2, 119.8, 116.4; MS (EI, 70 eV) m/z (%): 217, 172, 145, 108.




2-(pyridin-2-yl)thieno[2,3-*b*]pyridine^[2]

¹H NMR (CDCl₃, 400 MHz) δ 8.64 (4.0 Hz, 1H), 8.55 (4.0 Hz, 1H), 8.02 (d, J = 8.0 Hz, 1H), 7.86 – 7.67 (m, 3H), 7.28-7.21(m, 2H); ¹³C NMR (CDCl₃, 100 MHz) δ 162.3, 151.9, 149.7, 147.1, 144.9, 136.6, 133.9, 131.2, 123.1, 119.7, 119.6, 118.3; MS (EI, 70 eV) m/z (%): 212, 184, 168.




5-chloro-2-phenylthieno[2,3-*b*]pyridine

^1H NMR (CDCl_3 , 400 MHz) δ 8.46 (s, 1H), 7.98 (s, 1H), 7.70 (d, $J = 7.6$ Hz, 2H), 7.45 (t, $J = 7.4$ Hz, 2H), 7.40 (d, $J = 11.4$ Hz, 2H); ^{13}C NMR (CDCl_3 , 100 MHz) δ 159.1, 147.0, 145.1, 135.0, 133.5, 129.7, 129.2, 129.1 (2C), 126.6 (2C), 125.6, 115.8; MS (EI, 70 eV) m/z (%): 247, 245 (100%), 177, 166, 139; HRMS (EI) calcd for $\text{C}_{13}\text{H}_8\text{ClNS}$ (M^+) 245.0066; found, 245.0061.




5-methyl-2-phenylthieno[2,3-*b*]pyridine

^1H NMR (CDCl_3 , 400 MHz) δ 8.34 (s, 1H), 7.76 (s, 1H), 7.69 (d, $J = 7.6$ Hz, 2H), 7.48 – 7.29 (m, 4H), 7.25 (s, 1H), 2.41 (s, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ 158.7, 147.5, 144.5, 134.1, 133.9, 130.7, 129.3, 128.9 (2C), 128.6, 126.4 (2C), 116.3, 18.4; MS (EI, 70 eV) m/z (%): 225, 191, 176, 133; HRMS (EI) calcd for $\text{C}_{14}\text{H}_{11}\text{NS}$ (M^+) 225.0612; found, 225.0605.




2-heptylthieno[2,3-*b*]pyridine

^1H NMR (CDCl_3 , 400 MHz) δ 8.45 (dd, $J = 4.6, 1.5$ Hz, 1H), 7.88 (dd, $J = 8.0, 1.5$ Hz, 1H), 7.22 (dd, $J = 8.0, 4.7$ Hz, 1H), 6.91 (s, 1H), 2.90 (t, $J = 7.6$ Hz, 2H), 1.75 (dt, $J = 15.2, 7.6$ Hz, 2H), 1.41-1.24 (m, 8H), 0.88 (t, $J = 5.2$ Hz, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ 161.5, 147.5, 145.4, 133.6, 129.7, 119.3, 117.7, 31.7, 31.3, 30.9, 29.0, 28.97, 22.6, 14.0; MS (EI, 70 eV) m/z (%): 233, 200, 162, 149, 148; HRMS (EI) calcd for $\text{C}_{14}\text{H}_{19}\text{NS}$ (M^+) 233.1238; found, 233.1231.




2-cyclopentylthieno[2,3-*b*]pyridine

^1H NMR (CDCl_3 , 400 MHz) δ 8.44 (d, $J = 4.0$ Hz, 1H), 7.88 (d, $J = 7.9$ Hz, 1H), 7.24 – 7.13 (m, 1H), 6.93 (s, 1H), 3.32 (dd, $J = 15.3, 7.8$ Hz, 1H), 2.31 – 2.09 (m, 2H), 1.88 – 1.65 (m, 6H); ^{13}C NMR (CDCl_3 , 100 MHz) δ 161.3, 152.3, 145.4, 133.5, 129.7, 119.3, 116.2, 42.1, 34.8, 25.2; MS (EI, 70 eV) m/z (%): 203, 189, 174, 161, 148; HRMS (EI) calcd for $\text{C}_{12}\text{H}_{13}\text{NS}$ (M^+) 203.0769; found, 203.0762.




2-(3-phenylpropyl)thieno[2,3-*b*]pyridine

^1H NMR (CDCl_3 , 400 MHz) δ 8.45 (d, $J = 4.0$ Hz, 1H), 7.88 (d, $J = 8.0$ Hz, 1H), 7.29 (t, $J = 7.4$ Hz, 2H), 7.23-7.08 (m, 4H), 6.91 (s, 1H), 2.93 (t, $J = 7.6$ Hz, 2H), 2.71 (t, $J = 7.6$ Hz, 2H), 2.16 – 2.01 (m, 2H); ^{13}C NMR (CDCl_3 , 100 MHz) δ 161.38, 146.79, 145.39, 141.44, 133.55, 129.80, 128.41, 128.36, 125.92, 119.33, 118.04, 77.32, 77.00, 76.68, 35.02, 32.27, 30.61; MS (EI, 70 eV) m/z (%): 253, 239, 218, 204, 161, 129, 91; HRMS (EI) calcd for $\text{C}_{16}\text{H}_{15}\text{NS}$ (M^+) 253.0925; found, 253.0919.



2-(oct-3-ynyl)thieno[2,3-*b*]pyridine


^1H NMR (CDCl_3 , 400 MHz) δ 8.44 (dd, $J = 4.6, 1.3$ Hz, 1H), 7.88 (dd, $J = 8.0, 1.4$ Hz, 1H), 7.20 (dd, $J = 8.0, 4.7$ Hz, 1H), 6.97 (s, 1H), 3.07 (t, $J = 7.2$ Hz, 2H), 2.57 (tt, $J = 7.2, 2.3$ Hz, 2H), 2.13 (tt, $J = 7.0, 2.3$ Hz, 2H), 1.50 – 1.39 (m, 2H), 1.34 (dd, $J = 15.0, 7.2$ Hz, 2H), 0.85 (t, $J = 7.2$ Hz, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ 161.5, 145.5, 145.1, 133.3, 129.9, 119.3, 118.5, 82.0, 78.3, 31.1, 30.9, 21.8, 20.5, 18.3, 13.5; MS (EI, 70 eV) m/z (%): 243, 201, 186, 148; HRMS (EI) calcd for $\text{C}_{15}\text{H}_{17}\text{NS}$ (M^+) 243.1082; found, 243.1078.



2-(4-(thieno[2,3-*b*]pyridin-2-yl)butyl)thieno[2,3-*b*]pyridine


^1H NMR (400 MHz, DMSO-d_6) δ 8.48 (dd, $J = 4.4, 1.6$ Hz, 2H), 8.13 (dd, $J = 8.0, 1.6$ Hz, 2H), 7.40 (dd, $J = 8.0, 4.6$ Hz, 2H), 7.19 (s, 2H), 3.01 (t, $J = 6.6$ Hz, 4H), 1.88 – 1.74 (m, 4H);

^{13}C NMR (CDCl_3 , 100 MHz) δ 161.4 (2C), 146.5 (2C), 145.5 (2C), 133.6 (2C), 129.8 (2C), 119.4 (2C), 118.1 (2C), 30.9 (2C), 30.1 (2C).




2-(thieno[2,3-*b*]pyridin-2-yl)propan-2-ol

^1H NMR (CDCl_3 , 400 MHz) δ 8.50 (s, 1H), 8.02 – 7.86 (m, 1H), 7.27 (dd, $J = 7.6, 4.4$ Hz, 1H), 7.12 (d, $J = 3.3$ Hz, 1H), 2.76 (s, 1H), 1.75 (s, 3H), 1.75 (s, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ 161.1, 155.9, 145.7, 133.4, 130.6, 119.4, 115.5, 71.5, 31.9 (2C); MS (EI, 70 eV) m/z (%): 193, 178, 160, 136, 116; HRMS (EI) calcd for $\text{C}_{10}\text{H}_{11}\text{NOS}$ (M^+) 193.0561; found, 193.0557.




2-(thieno[2,3-*b*]pyridin-2-yl)butan-2-ol

^1H NMR (CDCl_3 , 400 MHz) δ 8.34 (d, $J = 3.8$ Hz, 1H), 7.81 (d, $J = 7.6$ Hz, 1H), 7.12 (dd, $J = 7.2, 5.4$ Hz, 1H), 6.97 (s, 1H), 3.11 (s, 1H), 1.84 (q, $J = 7.6$ Hz, 2H), 1.57 (s, 3H), 0.83 (t, $J = 7.6$ Hz, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ 161.1, 154.8, 145.5, 133.4, 130.5, 119.3, 116.1, 74.2, 37.0, 29.4, 8.3; MS (EI, 70 eV) m/z (%): 207, 189, 178, 174, 160, 136; HRMS (EI) calcd for $\text{C}_{11}\text{H}_{13}\text{NOS}$ (M^+) 207.0718; found, 207.0711.




3-(thieno[2,3-*b*]pyridin-2-yl)pentan-3-ol

^1H NMR (CDCl_3 , 400 MHz) δ 8.45 (d, $J = 3.1$ Hz, 1H), 7.91 (d, $J = 8.0$ Hz, 1H), 7.24-7.21 (m, 1H), 7.05 (s, 1H), 2.74 (s, 1H), 1.91 (q, $J = 7.6$ Hz, 4H), 0.89 (t, $J = 7.6$ Hz, 6H); ^{13}C NMR (CDCl_3 , 100 MHz) δ 161.4, 153.1, 145.5, 133.5, 130.4, 119.3, 116.9, 77.1, 35.1 (2C), 7.8 (2C); MS (EI, 70 eV) m/z (%): 221, 207, 204, 192, 174, 136; HRMS (EI) calcd for $\text{C}_{12}\text{H}_{15}\text{NOS}$ (M^+) 221.0874; found, 221.0867.




2-cyclohexenylthieno[2,3-*b*]pyridine

^1H NMR (CDCl_3 , 400 MHz) δ 8.42 (d, $J = 4.6$ Hz, 1H), 7.84 (d, $J = 8.0$ Hz, 1H), 7.18-7.15 (m, 1H), 6.97 (s, 1H), 6.33 (s, 1H), 2.45 (s, 2H), 2.23 (d, $J = 2.0$ Hz, 2H), 1.81-1.75 (m, 2H), 1.69-1.65 (m, 2H); ^{13}C NMR (CDCl_3 , 100 MHz) δ 160.6, 146.9, 145.8, 134.0, 131.3, 123.0, 128.6, 119.4, 114.8, 26.5, 25.8, 22.4, 21.9; MS (EI, 70 eV) m/z (%): 215, 200, 186, 148; HRMS (EI) calcd for $\text{C}_{13}\text{H}_{13}\text{NS}$ (M^+) 215.0769; found, 215.0762.




1-(thieno[2,3-*b*]pyridin-2-yl)propan-1-ol

^1H NMR (400 MHz, DMSO-d_6) δ 8.51 (dd, $J = 4.4, 1.2$ Hz, 1H), 8.18 (d, $J = 8.0$ Hz, 1H), 7.41 (dd, $J = 8.0, 4.6$ Hz, 1H), 7.27 (s, 1H), 5.84 (s, 1H), 4.84 (t, $J = 6.0$ Hz, 1H), 1.81 (p, $J = 7.2$ Hz, 2H), 0.95 (t, $J = 7.6$ Hz, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ 161.3, 150.1, 146.0, 133.1, 130.7, 119.5, 117.3, 72.3, 31.9, 9.9; MS (EI, 70 eV) m/z (%): 193, 189, 174, 164, 136; HRMS (EI) calcd for $\text{C}_{10}\text{H}_{11}\text{NOS}$ (M^+) 193.0561; found, 193.0557.



2,2,2-trifluoro-1-phenyl-1-(thieno[2,3-*b*]pyridin-2-yl)ethanol


^1H NMR (CDCl_3 , 400 MHz) δ 8.45 (d, $J = 4.0$ Hz, 1H), 7.99 (d, $J = 8.0$ Hz, 1H), 7.66 (s, 2H), 7.4—7.25 (m, 3H), 7.28-7.25 (m, 1H), 5.28 (s, 1H); ^{13}C NMR (CDCl_3 , 100 MHz) δ 161.1, 146.8, 144.9, 137.4, 132.6, 131.8, 129.2, 128.9 (q, $J = 3.0$ Hz, 1C), 128.3 (2C), 127.0 (2C), 120.8, 119.8, 29.7; MS (EI, 70 eV) m/z (%): 309, 240, 162, 105, 77; HRMS (EI) calcd for $\text{C}_{15}\text{H}_{10}\text{F}_3\text{NOS}$ (M^+) 309.0435; found, 309.0428.



2-phenylthieno[3,2-*b*]pyridine^[2]


^1H NMR (CDCl_3 , 400 MHz) δ 8.63 (d, $J = 4.0$ Hz, 1H), 8.05 (d, $J = 8.0$ Hz, 1H), 7.78 – 7.66 (m, 3H), 7.38 (dt, $J = 24.5, 7.2$ Hz, 3H), 7.14 (dd, $J = 7.9, 4.7$ Hz, 1H); ^{13}C NMR (CDCl_3 , 100

MHz) δ 156.7, 148.2, 147.3, 133.5, 133.3, 129.9, 129.0, 128.9 (2C), 126.3 (2C), 120.4, 118.5; MS (EI, 70 eV) m/z (%): 211, 167, 105.




5-methyl-2-phenylthieno[3,2-*b*]pyridine

^1H NMR (CDCl_3 , 400 MHz) δ 7.90 (d, $J = 8.0$ Hz, 1H), 7.68 (d, $J = 6.8$ Hz, 3H), 7.39 (t, $J = 7.2$ Hz, 2H), 7.33 (d, $J = 7.2$ Hz, 1H), 7.01 (d, $J = 8.0$ Hz, 1H), 2.64 (s, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ 156.3, 156.0, 147.9, 133.6, 130.4, 129.9, 128.9 (2C), 128.8, 126.2 (2C), 120.1, 118.8, 24.4; MS (EI, 70 eV) m/z (%): 225, 197, 139, 112; HRMS (EI) calcd for $\text{C}_{14}\text{H}_{11}\text{NS}$ (M^+) 225.0612; found, 225.0607.




2-(2,4-dimethylphenyl)thieno[2,3-*c*]pyridine

^1H NMR (CDCl_3 , 400 MHz) δ 9.09 (s, 1H), 8.49 (d, $J = 5.4$ Hz, 1H), 7.62 (d, $J = 5.4$ Hz, 1H), 7.35 (d, $J = 7.6$ Hz, 1H), 7.22 (s, 1H), 7.12 (s, 1H), 7.07 (d, $J = 7.6$ Hz, 1H), 2.42 (s, 3H), 2.37 (s, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ 149.7, 145.2, 143.9, 143.1, 138.93, 136.4, 136.0, 131.6, 130.3, 130.1, 126.7, 121.5, 117.3, 21.0, 20.8; MS (EI, 70 eV) m/z (%): 239; 224, 116; HRMS (EI) calcd for $\text{C}_{15}\text{H}_{13}\text{NS}$ (M^+) 239.0769; found, 239.0762.




7-chloro-2-phenylthieno[2,3-*c*]pyridine

^1H NMR (CDCl_3 , 400 MHz) δ 8.21 (d, $J = 5.2$ Hz, 1H), 7.70 – 7.59 (m, 2H), 7.46 (d, $J = 7.8$ Hz, 2H), 7.43 – 7.35 (m, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ 151.1, 147.7, 144.4, 143.2, 134.6, 132.6, 129.6, 129.0 (2C), 126.7 (2C), 118.7, 116.6; MS (EI, 70 eV) m/z (%): 245, 210, 177, 139; HRMS (EI) calcd for $\text{C}_{13}\text{H}_8\text{ClNS}$ (M^+) 245.0066; found, 245.0061.




4-chloro-2-phenylthieno[3,2-*c*]pyridine

^1H NMR (CDCl_3 , 400 MHz) δ 8.53 (d, $J = 4.4$ Hz, 1H), 8.01 (d, $J = 8.0$ Hz, 1H), 7.57 (s, 4H), 7.44 (s, 1H), 7.31-7.28 (m, 1H); ^{13}C NMR (CDCl_3 , 100 MHz) δ 161.4, 146.6, 143.1, 134.1, 132.8, 132.2 (2C), 130.8, 128.0 (2C), 122.9, 119.9, 117.1; MS (EI, 70 eV) m/z (%): 245, 210, 177, 139; HRMS (EI) calcd for $\text{C}_{13}\text{H}_8\text{ClNS}$ (M^+) 245.0066; found, 245.0063.




6-(4-chlorophenyl)thieno[3,2-*d*]pyrimidine

^1H NMR (CDCl_3 , 400 MHz) δ 9.20 (d, $J = 7.6$ Hz, 2H), 7.71 (d, $J = 6.0$ Hz, 3H), 7.47 (d, $J = 8.4$ Hz, 2H); ^{13}C NMR (CDCl_3 , 100 MHz) δ 161.4, 154.8, 150.9, 136.5, 131.2, 129.9, 129.6 (2C), 128.7, 128.2 (2C), 119.9; MS (EI, 70 eV) m/z (%): 248, 246, 192, 157, 113; HRMS (EI) calcd for $\text{C}_{12}\text{H}_7\text{ClN}_2\text{S}$ (M^+) 246.0018; found, 246.0012.




2-phenylfuro[2,3-*b*]pyridine^[3]

^1H NMR (CDCl_3 , 400 MHz) δ 8.28 (dd, $J = 4.9, 1.6$ Hz, 1H), 7.95 – 7.83 (m, 3H), 7.45 (t, $J = 7.6$ Hz, 2H), 7.38 (t, $J = 7.4$ Hz, 1H), 7.20 (dd, $J = 7.6, 4.9$ Hz, 1H), 6.98 (s, 1H); ^{13}C NMR (CDCl_3 , 100 MHz) δ 161.8, 155.5, 143.6, 129.5, 129.5, 129.2, 128.8 (2C), 125.1 (2C), 121.4, 119.5, 100.0; MS (EI, 70 eV) m/z (%): 195 (100%), 166, 139.




2-(2,4-dimethylphenyl)furo[2,3-*b*]pyridine

^1H NMR (CDCl_3 , 400 MHz) δ 8.28 (d, $J = 2.8$ Hz, 1H), 7.86 (d, $J = 7.6$ Hz, 1H), 7.79 (d, $J = 7.6$ Hz, 1H), 7.18 (dd, $J = 6.8, 4.4$ Hz, 1H), 7.10 (d, $J = 11.6$ Hz, 2H), 6.79 (d, $J = 2.0$ Hz, 1H), 2.54 (s, 3H), 2.34 (s, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ 161.3, 155.6, 143.5, 139.0, 135.8, 132.0, 129.2, 128.2, 126.8, 126.1, 121.3, 119.2, 103.1, 21.8, 21.1; MS (EI, 70 eV) m/z (%): 223 (100%), 208, 194, 180.




2-(4-butylphenyl)furo[2,3-*b*]pyridine

^1H NMR (CDCl_3 , 400 MHz) δ 8.29 (d, $J = 4.8$ Hz, 1H), 7.86 (dd, $J = 18.4, 7.6$ Hz, 3H), 7.29 (d, $J = 7.6$ Hz, 2H), 7.21 (dd, $J = 7.2, 5.2$ Hz, 1H), 6.96 (s, 1H), 2.68 (t, $J = 7.7$ Hz, 2H), 1.73 – 1.58 (m, 2H), 1.52 – 1.34 (m, 2H), 0.96 (t, $J = 7.3$ Hz, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ 161.8, 155.9, 144.5, 143.4, 129.2, 128.9 (2C), 127.0, 125.1 (2C), 121.6, 119.4, 99.2, 35.49, 33.4, 22.3, 13.9; MS (EI, 70 eV) m/z (%): 251, 208 (100%).




2-(4-methoxyphenyl)furo[2,3-*b*]pyridine^[3]

^1H NMR (CDCl_3 , 400 MHz) δ 8.24 (dd, $J = 4.8, 1.6$ Hz, 1H), 7.84-7.81 (m, 3H), 7.18 (dd, $J = 7.6, 4.9$ Hz, 1H), 7.02 – 6.95 (m, 2H), 6.84 (d, $J = 3.7$ Hz, 1H), 3.85 (s, 3H); ^{13}C NMR (CDCl_3 , 100 MHz) δ 161.8, 160.5, 155.7, 143.1, 129.0, 126.7 (2C), 122.3, 121.7, 119.4, 114.3 (2C), 98.3, 55.3; MS (EI, 70 eV) m/z (%): 225 (100%), 210, 182.



2-(4-chlorophenyl)furo[2,3-*b*]pyridine


^1H NMR (CDCl_3 , 400 MHz) δ 8.27 (d, $J = 4.0$ Hz, 1H), 7.85 (d, $J = 7.6$ Hz, 1H), 7.77 (d, $J = 7.6$ Hz, 2H), 7.38 (d, $J = 7.6$ Hz, 2H), 7.23 – 7.13 (m, 1H), 6.93 (s, 1H); ^{13}C NMR (CDCl_3 , 100 MHz) δ 161.7, 154.3, 144.0, 135.0, 129.6, 129.0 (2C), 127.9, 126.2 (2C), 121.2, 119.6, 100.4; MS (EI, 70 eV) m/z (%): 231, 229 (100%), 166, 139.



2-(4-bromophenyl)furo[2,3-*b*]pyridine

^1H NMR (CDCl_3 , 400 MHz) δ 8.30 (dd, $J = 4.8, 1.4$ Hz, 1H), 7.90 (dd, $J = 7.6, 1.6$ Hz, 1H), 7.80 – 7.72 (m, 2H), 7.59 (d, $J = 8.6$ Hz, 2H), 7.22 (dd, $J = 7.6, 4.9$ Hz, 1H), 7.00 (s, 1H); ^{13}C

NMR (CDCl₃, 100 MHz) δ 161.8, 154.5, 144.2, 132.1 (2C), 129.7, 128.5, 126.6 (2C), 123.4, 121.3, 119.7, 100.5; MS (EI, 70 eV) m/z (%): 275 (100%), 273, 166, 139.





2-(3-bromophenyl)furo[2,3-*b*]pyridine



¹H NMR (CDCl₃, 400 MHz) δ 8.31 (d, *J* = 3.6 Hz, 1H), 8.01 (s, 1H), 7.88 (d, *J* = 7.6 Hz, 1H), 7.79 (d, *J* = 7.8 Hz, 1H), 7.48 (d, *J* = 8.0 Hz, 1H), 7.30 (t, *J* = 8.0 Hz, 1H), 7.24 – 7.17 (m, 1H), 6.98 (s, 1H); ¹³C NMR (CDCl₃, 100 MHz) δ 161.7, 153.7, 144.3, 132.0, 131.4, 130.3, 129.8, 127.9, 123.5, 122.9, 121.0, 119.6, 101.0; MS (EI, 70 eV) m/z (%): 275 (100%), 273, 166, 139.



References:



- (1) Shen, C.; Spannenberg, A.; Wu, X. F. *Angew. Chem. Int. Ed.*, 2016, **128**, 5151-5154.
- (2) Peixoto, D.; Begouin, A.; Queiroz, M. J. B. P. *Tetrahedron*, 2012, **68**, 7082-7094.
- (3) Hudson, R.; Bizier, N. P.; Esdale, K. N.; Katz, J. L. *Org. Biomol. Chem.*, 2015, **13**, 2273-2284.



V. NMR Data





















8.436
 8.426
 7.925
 7.905
 7.586
 7.229
 6.764
 6.742



3.015







161.040
 150.704
 145.197
 134.829
 127.487
 119.594
 113.558
 112.343
 77.318
 77.000
 76.683
 40.337

























8.565
8.555
8.059
7.704
7.538
7.332
7.319
7.312
7.301





161.661
146.977
142.598
133.957
131.144
125.974
120.069
118.279

77.317
77.000
76.682









8.643
8.633
8.551
8.541
8.029
8.009
7.708
7.281
7.273
7.270
7.261
7.250
7.240
7.227
7.210



162.280
151.944
149.727
147.028
144.902
136.640
133.894
131.212
123.021
119.718
118.575
118.313
77.318
77.000
76.883







8.460
7.976
7.695
7.473
7.454
7.436
7.413
7.385
7.260



159.105
147.017
145.058
134.985
133.449
129.130
126.621
125.606
115.765



77.318
77.000
76.683







8.452
8.449
8.442
8.439
7.890
7.887
7.878
7.871
7.212
7.203
- 6.906

2.914
2.889
2.884
1.765
1.751
1.736
1.720
1.320
1.277
0.893
0.880
0.866





161.484
147.526
145.354
133.619
129.697
119.282
117.715
77.255
77.000
76.746
31.702
31.276
30.846
29.029
28.973
22.597
14.044







8.447
8.437
7.886
7.886
7.229
7.214
7.198
6.933



3.348
3.329
3.310
3.291
2.189
2.179
2.162
1.841
1.821
1.804
1.776
1.736



161.248
152.264
145.346
133.518
129.731
119.289
116.222
77.317
77.000
76.682
42.142
34.804
25.229









DMSO-d6 as solvent

8.490
8.486
8.479
8.475
— 8.116
7.411
7.400
7.391
7.380
7.192

3.030
3.014
2.997
2.531
1.845
1.835
1.828
1.820
1.810







CDCl3 as solvent




— 161.393
146.543
145.453
133.547
129.833
119.359
118.058



77.317
77.000
76.682



30.895
30.086

















DMSO-d6 as solvent



8.515
8.512
8.503
8.501
8.168
7.430
7.419
7.410
7.399
7.269
5.836
4.851
4.836
4.820
2.540
1.806
1.788
1.770
0.966
0.948
0.929







161.283
150.080
145.991
133.067
130.709
119.539
117.334
77.317
77.000
76.682
72.338
31.874
9.853

















8.214
8.201
7.661
7.645
7.642
7.472
7.453
7.426
7.419
7.407
7.390
7.358
7.260





151.094
147.669
144.413
143.162
132.587
129.574
129.043
126.655
118.677
116.633

77.317
77.000
76.682











9.210
9.191
7.721
7.706
7.485
7.464







161.388
154.771
150.931
136.506
129.613
128.730
128.158
119.873
77.317
77.000
76.682

















8.310
8.307
8.300
8.297
7.892
7.751
7.577
7.225
6.999



161.813
154.478
144.156
132.095
129.697
128.505
126.566
123.400
121.275
119.670
100.536
77.255
77.000
76.746

